Incyte (INCY) Heads To ESMO With New Oncology Data, Is The Stock Still Undervalued?

Incyte (INCY) is back in focus as it prepares to present new oncology data at the European Society for Medical Oncology Congress in Madrid, covering several high-need solid tumor programs. That interest is landing on a stock that has been choppy in the short term but strong over longer periods, with Incyte’s 30 day share price return down 7.16% even as the year to date move sits at a 14.09% gain and the 3 year total shareholder return reaches 120.23%. This suggests sentiment has cooled...